Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Mydecine Innovations Group Inc.
Mydecine Innovations Group Inc. News
Mydecine Innovations Group Inc. Quantitative Score
About Mydecine Innovations Group Inc.
Mydecine Innovations Group Inc., a biotech and life sciences company, engages in the development and commercialization of drugs for treating mental health problems. It develops therapies for veterans, emergency medical service providers, post-traumatic stress disorder, and front-line workers; and operates Mindleap, a digital telehealth platform that provides access to mental health services, as well as psychedelic integration services, including psychedelic aftercare and wellness services. The company also engages in the drug discovery and builds nature-sourced psychedelic-assisted therapeutics, compounds, therapy protocols, and unique delivery systems. In addition, it operates hemp farm in Pottus, Texas. Mydecine Innovations Group Inc. has a partnership with Leiden University Medical Center; Royal Ottawa Mental Health Centre; LeadGen Labs to support psychedelic drug development; and Applied Pharmaceutical Innovation for drug development and clinical trial programs. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
Mydecine Innovations Group Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Mydecine Innovations Group Inc. Financials
Table Compare
Compare MYCOF metrics with: | |||
|---|---|---|---|
Earnings & Growth | MYCOF | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | MYCOF | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | MYCOF | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | MYCOF | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Mydecine Innovations Group Inc. Income
Mydecine Innovations Group Inc. Balance Sheet
Mydecine Innovations Group Inc. Cash Flow
Mydecine Innovations Group Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Buy |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Neutral |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Mydecine Innovations Group Inc. Executives
| Name | Role |
|---|---|
| Mr. Robert Roscow M.A. | Co-Founder & Former Chief Scientific Officer |
| Mr. Damon Michaels | Co-Founder |
| Mr. David Joshua Bartch | Co-Founder, Chief Executive Officer, President & Chairman of the Board |
| Dr. Rakesh Jetly FRCPC, M.D. | Chief Medical Officer |
| Mr. John Charles Ross CA, CPA, M.B.A. | Chief Financial Officer & Corporate Secretary |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Robert Roscow M.A. | Co-Founder & Former Chief Scientific Officer | Male | 326.27K | |
| Mr. Damon Michaels | Co-Founder | Male | 326.27K | |
| Mr. David Joshua Bartch | Co-Founder, Chief Executive Officer, President & Chairman of the Board | Male | 1988 | 318.53K |
| Dr. Rakesh Jetly FRCPC, M.D. | Chief Medical Officer | 194.34K | ||
| Mr. John Charles Ross CA, CPA, M.B.A. | Chief Financial Officer & Corporate Secretary | Male | 1958 | 6.59K |